Complete Content of this Issue and Cover Content 2 0 0 2016/10/26 1395/8/5 2016/10/26 1395/8/5 ## ##

Platelet Factor 3 Based-clotting Time Assay as a Quality Marker for Long-term Storage of Platelet Concentrates فاکتور 3 پلاکنی بر پایه زمان انعقادی ممکن است ضریب همبستگی بهتری را در مقایسه با pH هنگام نگهداری طولانی مدت پلاکت های کنسانتره نشان دهد 2 2 Background: Platelets rapidly lose their qualities usually after 5 day of storage. Different standard methods have been recommended to check the quality of platelets during storage which some of them show better correlation with other quality markers during storage. The purpose of this study was to demonstrate if platelet factor 3 (PF3) assay could be an indicator of storage lesion and provide a significant correlation with other quality markers during long-term storage of platelet concentrates (PC) up to 11 days. Methods: Twelve random units of PC were placed in a standard platelet incubator under continuous agitation at 22-24°C for eleven days. Samples were taken on days 1, 3, 5, 8 and 11. Parameters such as pH, glucose, lactate dehydrogenase (LDH), platelet count of the bags, mean platelet volume (MPV) and platelet distribution width (PDW) and PF3 were measured. The correlation coefficient of PF3 and pH with the abovementioned parameters was evaluated. Results: The mean percentage of changes for PF3, pH, glucose, LDH, platelet count, MPV and PDW on day 11 compared to the first day were found to be 61, 15, 52, 440, 19, 18 and 39%, respectively. After LDH, PF3 had the highest change relative to the other markers. PF3 demonstrated better correlation with glucose, platelet count, MPV and PDW compared with pH during long-term PC storage. Conclusion: Platelet factor 3 based-clotting time assay could be a potential candidate for monitoring the quality of PC due to apparent trend of its changes during storage with better correlation between the quality markers. 63 67 2016/10/262016/04/19 1395/1/31 2016/10/262016/06/14 1395/3/25 Saleh Nasiri Saleh Nasiri salehnasiri2012@gmail.com Fatemeh Abbasi Fatemeh Abbasi Platelet concentrate Platelet factor 3 pH LDH MPV Platelet storage lesions Quality marker Platelet recovery ## ##

The Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study 2 2 Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL. Methods: In the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (2010–2013), central Iran. Immunohistochemical method was used for detecting biomarkers such as CD2, CD3, CD20 and CD45. Result: In this study, 54.5% of the patients were men and 45.5% were women. Most of the patients were 40-50 years old. Moreover, 10 (22.7%) patients had lymph node metastasis and 6 (13.6%) patients had stomach involvement. Positive expression of CD45 and CD20 biomarkers were expressed in 100% and 97.7% of the patients. Positive expression of CD3 and CD2 was expressed in 40.9% and 81.8% of the patients, respectively. C-expression of CD45 and CD20 biomarkers was seen in 43 patients. Moreover, there was no relation between biomarkers and sex and age (P>0.05). Conclusion: The result of this study showed that high number of CD45 and CD20 have been seen in Iran’s population. Moreover expression of CD20 and CD45 is different as compared with other populations. It seems that these differences can be due to ethnic groups and nature of malignant cells. 68 71 2016/10/262016/04/192016/02/18 1394/11/29 2016/10/262016/06/142016/09/4 1395/6/14 Robab Sheikhpour Robab Sheikhpour r.sheikhpour@yahoo.com Fatemeh Pourhosseini Fatemeh Pourhosseini Diffuse large B cell lymphoma CD20 CD45 CD3 CD2 ## ##

The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran 2 2 Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients’ response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents. Methods: Hemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients’ preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview. Results: 80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products. Conclusion: Our results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential. 72 74 2016/10/262016/04/192016/02/182016/10/18 1395/7/27 2016/10/262016/06/142016/09/42016/10/18 1395/7/27 Behnaz Habibpanah Behnaz Habibpanah Zahra Tara Zahra Tara Fatemeh Malek Fatemeh Malek fmalek7721@gmail.com Rezvan Ardeshiri Rezvan Ardeshiri Tahmineh Salimi Tahmineh Salimi Belgheis Fasih Belgheis Fasih Mohammad Reza Managhchi Mohammad Reza Managhchi Hemophilic patients Patients’ response Bypassing agents ## ##

Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients 2 2 Background: The oncologic behavior of mucinous adenocarcinoma (MA) of colorectal differs from non-mucinous adenocarcinoma (NMA). MA is more advanced at diagnosis and has a poorer prognosis than NMA. We aimed to evaluate prognostic factors and survival rate in patients with MA compared with NMA in Western Iran. Methods: During 2008-2015 in a retrospective study, 83 patients with CRC referred to the Oncology Clinic in Kermanshah, Iran. Binary logistic regression analysis was used for the correlation between risk variables with the type of pathology. Results: The mean follow-up was 32 months (range, 12-72 months) and in this interval, there were 26 deaths and 3 patients were lost to follow-up and therefore, were omitted them from survival analysis. There was no significant correlation between NMA and MA with sex, degree of differentiation of tumor, tumor site, tumor size, KRAS mutation and lymph node metastasis, but a significant correlation was observed with age (P<0.05). Binary logistic regression analysis showed there was a significant correlation between age (P=0.01, odds ratio 11.93 and 95% CI 1.61-88.46) and type of pathology. The survival rate and mean survival were 54.3% and 23 months for NMA group, versus 80.6% and 25.4 months for MA group, respectively. Conclusion: The prevalence of NMA in CRC was more than MA. In this study, the MA patients had lower age and more risk of recurrence compared to NMA patients and unlike other studies, 5-year survival rate was significantly higher in NMA patients than that in MA patients. 75 79 2016/10/262016/04/192016/02/182016/10/182016/02/21 1394/12/2 2016/10/262016/06/142016/09/42016/10/182016/10/18 1395/7/27 Mehrdad Payandeh Mehrdad Payandeh md.payandeh@yahoo.com Masoud Sadeghi Masoud Sadeghi sadeghi_mbrc@yahoo.com Edris Sadeghi Edris Sadeghi fgholami@yahoo.com Colorectal cancer Survival Mucinous adenocarcinoma Non-mucinous adenocarcinoma Age ## ##

Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients 2 2 Background: The development of anti-red blood cell alloantibodies remains a major problem in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in clinical hemolysis and difficulty in cross-matching blood. We studied the frequency of red blood cell alloimmunization and autoimmunization among thalassemia patients who received regular transfusions in Ilam province of Iran. Methods: This study was carried out on 110 multiply transfused patients with thalassemia major. The saline method, Albumin method, direct/indirect coombs’ and Three cell panel test used for detection of red blood cell alloantibody/ autoantibody. Results: 12 patients out of total 110 patients (10.9 %) developed alloantibodies and 2 (1.81 %) developed autoantibodies. Rh and Kell blood group system alloantibodies were most commonly found, with the majority of patients being transfused with blood matched for ABO and D antigens only. Conclusion: This study suggests screening RBC antigens prior to transfusion. Our findings accentuate the necessity of antigen typing of supposed to be transfused red blood cells and screenings tests before the first transfusion, at least for Rh (Rh system) and Kell (Kell system) antigens. 80 85 2016/10/262016/04/192016/02/182016/10/182016/02/212016/06/21 1395/4/1 2016/10/262016/06/142016/09/42016/10/182016/10/182016/09/11 1395/6/21 Ali Ghasemi Ali Ghasemi Sadegh Abbasian Sadegh Abbasian sadegh_abasian@yahoo.com Kazem Ghaffari Kazem Ghaffari Zeynal Salmanpour Zeynal Salmanpour Alloimmunization Autoimmunization Thalassemia Transfusion ## ##

Lineage Switch in Childhood Leukemia: A Case Report and Review of Literature 2 2 Acute leukemia which is the most common cancer in children is a heterogeneous group of clonal malignancies. The conversion of the leukemic cell lineage during the course of the disease or later is termed lineage switch. It has been rarely reported in the literature. In leukemia lineage switch, conversions from lymphoblastic leukemia to myeloid leukemia or vice versa are reported. Herein, we report a 7-year-old child with acute lymphoblastic leukemia which switched to acute myeloid leukemia upon relapse. 86 87 2016/10/262016/04/192016/02/182016/10/182016/02/212016/06/212016/09/11 1395/6/21 2016/10/262016/06/142016/09/42016/10/182016/10/182016/09/112016/09/21 1395/6/31 Shiva Nazari Shiva Nazari Fatemeh Malek Fatemeh Malek fmalek7721@gmail.com Navid Zavvar Navid Zavvar Leukemia Children Cell lineage ## ##

Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia 2 88 89 2016/10/262016/04/192016/02/182016/10/182016/02/212016/06/212016/09/112015/08/25 1394/6/3 2016/10/262016/06/142016/09/42016/10/182016/10/182016/09/112016/09/212015/09/9 1394/6/18 Babak Abdolkarimi Babak Abdolkarimi b.abdolkarimi@yahoo.com ## ##

Portal Vein Thrombosis Following Splenectomy in β-thalassemia Major 2 90 91 2016/10/262016/04/192016/02/182016/10/182016/02/212016/06/212016/09/112015/08/252016/10/19 1395/7/28 2016/10/262016/06/142016/09/42016/10/182016/10/182016/09/112016/09/212015/09/92016/10/19 1395/7/28 Sara Sadeghi Sara Sadeghi sadeghisaramd@gmail.com Ahmad Mohammadi Ashiani Ahmad Mohammadi Ashiani Mitra Khalili Mitra Khalili ## ##